Business Wire

CGTN

11.6.2020 05:37:05 CEST | Business Wire | Press release

Share
CGTN: How China's Top-down Command System Helped Contain COVID-19?

China’s centralized and efficient command system formed a strong guarantee for the country to win the all-out people's war against COVID-19, according to a recently-released government white paper.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005922/en/

The document released on June 7 chronicled China's battle against COVID-19, detailing its painstaking yet effective efforts to control the outbreak domestically and its swift responses to contain the spread globally.

The coronavirus caught China unaware, the white paper noted, but the Chinese government acted swiftly to fight the virus and provide medical treatment for patients, prioritizing people's lives and health.

Since the first cases were detected in late December 2019, China has adopted thorough, rigorous and comprehensive prevention and control measures, as well as enforced quarantine and isolation, on a scale never seen before.

Medical resources have been mobilized across the country, and all those in need have been tested, quarantined, hospitalized or treated. With these measures in place, the country was able to contain the outbreak quickly and prevent a wider spread.

The white paper divides China's fight against the epidemic into five stages – "swift response" (December 27, 2019 to January 19, 2020), "initial containment" (January 20 to February 20), "single-digit increase in new domestic cases" (February 21 to March 17), "initial victory in a critical battle" (March 18 to April 28) and "epidemic control, new normal" (from April 29 onwards).

Timeline: China's fight against COVID-19 in five stages

Graphics: Inside China's all-out effort to contain the coronavirus

It took China more than three months to declare an initial victory in the COVID-19 battle, according to the white paper. This was possible as a result of the country's centralized and highly efficient command system, the white paper concluded.

Under the strong leadership of the CPC Central Committee with Xi Jinping at its core, central authorities exercise overall command while local authorities and all sectors follow the leadership and instructions of the central authorities, perform their respective duties and cooperate with each other.

President Xi assumed full command over the control efforts from the beginning of the outbreak. He chaired 14 meetings of the Standing Committee of the Political Bureau of the CPC Central Committee, four meetings of the Political Bureau, meetings of the Central Commission for Law-based Governance, Central Cyberspace Affairs Commission, Central Commission for Further Reform, and Central Commission for Foreign Affairs, and a meeting with prominent non-CPC figures. At these meetings, he heard briefings about epidemic prevention and control work and made decisions on overall plans for strengthening control efforts and international cooperation.

The president inspected community response and COVID-19 research in Beijing, and visited Wuhan to guide the frontline response. He has also inspected Zhejiang, Shaanxi, Shanxi and Gansu provinces, where he was briefed on progress in coordinating epidemic prevention and control with economic and social development, as well as in poverty alleviation.

Meanwhile, the central government coordinated the epidemic control work. Premier Li Keqiang, as head of the Central Leading Group for Novel Coronavirus Prevention and Control, chaired more than 30 meetings regarding COVID-19 control and economic resumption.

On January 7, Xi issued instructions on epidemic prevention and control work when he chaired a meeting of the Standing Committee of the Political Bureau of the CPC Central Committee.

On January 23, Wuhan, a megacity with a population of more than 10 million, was locked down in an unprecedented effort to contain the spread of the virus.

The central government mobilized medical experts and supplies as well as provisions for daily living needs such as food and energy to assist Wuhan and Hubei, and major public health emergency responses were activated across the country.

On January 25, the Standing Committee of the Political Bureau of the CPC Central Committee set up a central leading group on the epidemic, dispatched a central guiding team and demanded a State Council inter-agency task force play a full role in coordination.

The central leading group went to Wuhan to inspect and direct prevention and control of COVID-19 on January 27. Premier Li, who headed the leading group, also went to Wuhan to inspect the front lines.

In meetings with the CPC's senior leaders in early February, Xi called for measures to implement higher admission and treatment rates and lower infection and fatality rates. He also asked governments at all levels to implement targeted policies to contain the outbreak quickly.

Official data showed that many provinces started to lower their major public health emergency response levels from February 21, indicating the COVID-19 outbreak was coming under control.

On March 11, daily new domestic cases fell to single digits for the first time on the Chinese mainland. A week later, the mainland reported no increase in domestic cases for the first time.

As China declared an early victory in the containment of COVID-19 and normalized epidemic prevention and control, the CPC's top leadership made arrangements to steadily lift the travel restrictions and open up economic activity.

On May 7, the central government issued guidelines on normalized epidemic prevention and control.

Link:

ClickThru

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release

Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye